A Phase 2/3 interventional study of Cyclosporine NOVA22007 0.05% and Cyclosporine NOVA22007 0.1% in Conjunctivitis, Vernal, sponsored by Santen SAS. Completed at 1 site in France. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2021-12-14.
Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 2/3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Conjunctivitis, Allergic with a site in France — 1 open to participants now, 1 under way, 1 of them phase 3. Conjunctivitis, Allergic · France.
Among the 10 studies in Conjunctivitis, Allergic with a site in France, this one is the only one that started in 2006, is the only one in phase 2/3, and was the 1st registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →1 of the 10 studies in Conjunctivitis, Allergic with a site in France is open now. Recruiting first, the newest first:
Dompé Farmaceutici S.p.A · Sites in France, United States, Argentina and 11 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 118 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 160 across the 8 interventional studies, 38 across the 2 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 9 most frequent:
This study is registered under Santen SAS, one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen SAS is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Santen Pharmaceutical Co., Ltd. has 4 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Conjunctivitis, Allergic with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is:
The secondary objectives of this study are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least the two following signs, in at least one eye* (the same eye should fulfill both criteria):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
four times daily
Drug: Cyclosporine NOVA22007 0.05%
four times daily
Drug: Cyclosporine NOVA22007 0.1%
administered four times daily
Drug: Vehicle
Overall Rating of Subjective Symptoms of VKC in Period I
The primary criteria of the trial was the overall rating of subjective symptoms in ocular symptoms of VKC as compared to Baseline and assessed at Week 4 (Month 1) based on a five-point scale based on BenEzra trial (BenEzra 1986): 1. = Overall worsening of the subjective findings. 2. = No change in the symptoms. 3. = Slight improvement with the child still unable to participate in all normal daily activities. 4. = Marked improvement despite temporary mild itching or mucus discharge. 5. = Completely free of all symptoms.
Time frame: Week 4
Overall Rating of Objective Symptoms of VKC in Period I
Overall rating of objective signs was to be assessed under the slit lamp by the Investigator and recorded on a five-point scale based on BenEzra trial (BenEzra 1986): 1. Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement with the papillary proliferations more extensive or similar to the situation recorded before treatment in at least one of the eyes. 2. The overall condition was assessed as better than before treatment in both eyes. 3. Total re-epithelialisation of the cornea although slight conjunctival and perilimbal hyperaemia and papillary proliferations remains in both eyes. 4. Only slight conjunctival hyperaemia without perilimbal injection or papillary proliferations in at least one eye 5. Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection.
Time frame: Week 4
Change in Mean Daily Number of Unpreserved Artificial Tears Instillations in Period I
Time frame: Up to Month1
Ocular Tolerance in Period I
Are the tested eye drops (other than concomitant tear substitute ) comfortable?
Time frame: Up to Month1
| Milestone | Vehicle | NOVA22007 0.05% | NOVA22007 0.1% |
|---|---|---|---|
| Started | 40 | 39 | 39 |
| Completed | 36 | 39 | 36 |
| Not completed | 4 | 0 | 3 |
| Milestone | Vehicle | NOVA22007 0.05% | NOVA22007 0.1% |
|---|---|---|---|
| Started | 0 | 58 | 53 |
| Completed | 0 | 50 | 49 |
| Not completed | 0 | 8 | 4 |
The primary criteria of the trial was the overall rating of subjective symptoms in ocular symptoms of VKC as compared to Baseline and assessed at Week 4 (Month 1) based on a five-point scale based on BenEzra trial (BenEzra 1986): 1. = Overall worsening of the subjective findings. 2. = No change in the symptoms. 3. = Slight improvement with the child still unable to participate in all normal daily activities. 4. = Marked improvement despite temporary mild itching or mucus discharge. 5. = Completely free of all symptoms.
| Participants | Vehicle | NOVA22007 0.05% | NOVA22007 0.1% |
|---|---|---|---|
| 1- Overall worsening of the | 7 | 1 | 4 |
| 2- No change in the symptoms | 5 | 3 | 2 |
| 3- Slight improvement | 10 | 15 | 11 |
| 4- Marked improvement | 15 | 19 | 20 |
| 5- Completely free of all symptoms | 3 | 1 | 2 |
| instillations | Vehicle | NOVA22007 0.05% | NOVA22007 0.1% |
|---|---|---|---|
| Week1- Baseline | -0.5 ± 1.5 | 0.1 ± 2.2 | -0.1 ± 1.3 |
| Week2- Baseline | -0.2 ± 0.9 | -0.4 ± 1.4 | -0.2 ± 1.5 |
| Month1-Baseline | -0.4 ± 1.9 | -0.5 ± 1.5 | 0.0 ± 1.9 |
Are the tested eye drops (other than concomitant tear substitute ) comfortable?
| Participants | Vehicle | NOVA22007 0.05% | NOVA22007 0.1% |
|---|---|---|---|
| Week1 — No | 3 | 11 | 4 |
| Week1 — Yes | 35 | 24 | 34 |
| Week2 — No | 3 | 5 | 6 |
| Week2 — Yes | 34 | 33 | 31 |
| Month1 — No | 2 | 8 | 7 |
| Month1 — Yes | 34 | 31 | 29 |
Overall rating of objective signs was to be assessed under the slit lamp by the Investigator and recorded on a five-point scale based on BenEzra trial (BenEzra 1986): 1. Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement with the papillary proliferations more extensive or similar to the situation recorded before treatment in at least one of the eyes. 2. The overall condition was assessed as better than before treatment in both eyes. 3. Total re-epithelialisation of the cornea although slight conjunctival and perilimbal hyperaemia and papillary proliferations remains in both eyes. 4. Only slight conjunctival hyperaemia without perilimbal injection or papillary proliferations in at least one eye 5. Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection.
| Participants | Vehicle | NOVA22007 0.05% | NOVA22007 0.1% |
|---|---|---|---|
| 1.Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement. | 18 | 8 | 7 |
| 2.The overall condition was assessed as better than before treatment in both eyes. | 13 | 17 | 16 |
| 3.Total re-epithelialisation of the cornea | 4 | 7 | 12 |
| 4.Only slight conjunctival hyperaemia in at least one eye | 4 | 6 | 2 |
| 4.Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection. | 1 | 1 | 2 |
Collected over From the time the patient gave informed consent until the last trial visit at month 4.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/40 (0%) | 0/40 (0%) | 14/40 (35%) |
| Period I- NOVA22007 0.05% | 0/39 (0%) | 0/39 (0%) | 14/39 (35.9%) |
| Period I-NOVA22007 0.1% | 0/39 (0%) | 0/39 (0%) | 12/39 (30.8%) |
| Period II- NOVA22007 0.05% | 0/58 (0%) | 1/58 (1.7%) | 17/58 (29.3%) |
| Period II-NOVA22007 0.1% | 0/53 (0%) | 0/53 (0%) | 11/53 (20.8%) |
| Event | Placebo | Period I- NOVA22007 0.05% | Period I-NOVA22007 0.1% | Period II- NOVA22007 0.05% | Period II-NOVA22007 0.1% |
|---|---|---|---|---|---|
| ASTHMARespiratory, thoracic and mediastinal disorders | 0/40 | 0/39 | 0/39 | 1/58 | 0/53 |
| Event | Placebo | Period I- NOVA22007 0.05% | Period I-NOVA22007 0.1% | Period II- NOVA22007 0.05% | Period II-NOVA22007 0.1% |
|---|---|---|---|---|---|
| Allergic keratitisEye disorders | 9/40 | 3/39 | 8/39 | 1/58 | 0/53 |
| Instillation site pruritusGeneral disorders | 1/40 | 5/39 | 4/39 | 3/58 | 1/53 |
| Instillation Site IrritationGeneral disorders | 0/40 | 4/39 | 2/39 | 2/58 | 4/53 |
| Visual acuity reducedEye disorders | 1/40 | 0/39 | 3/39 | 3/58 | 1/53 |
| Corneal UlcerEye disorders | 3/40 | 0/39 | 0/39 | 1/58 | 0/53 |
| Drug intoleranceGeneral disorders | 0/40 | 2/39 | 0/39 | 4/58 | 1/53 |
| Ocular hyperaemiaEye disorders | 1/40 | 2/39 | 2/39 | 0/58 | 0/53 |
| Instillation site painGeneral disorders | 2/40 | 0/39 | 1/39 | 0/58 | 1/53 |
| BlepharitisEye disorders | 0/40 | 0/39 | 1/39 | 0/58 | 0/53 |
| HyperthermiaGeneral disorders | 0/40 | 1/39 | 0/39 | 0/58 | 0/53 |
| Age, Customized(years) | NOVA22007 0.05% | NOVA22007 0.1% | Vehicle | Total |
|---|---|---|---|---|
| Age | 8.5 ± 2.9 | 9.4 ± 3.7 | 8.5 ± 2.4 | 8.8 ± 3.9 |
| Sex: Female, Male(Participants) | NOVA22007 0.05% | NOVA22007 0.1% | Vehicle | Total |
|---|---|---|---|---|
| Female | 5 | 6 | 11 | 22 |
| Male | 34 | 33 | 29 | 96 |
The record gives a start of May 2006 and a primary completion of Feb 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2021, 14 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.